This site is intended for healthcare professionals

New data reinforces improved and durable responses of Orencia in moderate-to-severe early rheumatoid arthritis patients with autoantibodies linked to more severe disease. - BMS

Read time: 2 mins
Last updated:16th Mar 2021
Published:4th Jun 2020
Condition: Rheumatoid Arthritis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest